Physician profile
Todd D Severin
NPI 1144225343
$87,512.90
in general payments reported to CMS, 2019-2025
28 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $1,605 · 2021: $3,800 · 2022: $7,060 · 2023: $3,153 · 2024: $1,073 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036 · Consulting Fee: $2,000 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,036.38 |
| Consulting Fee | $2,000.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $58,923.89 | 2019-2024 | Cirrus Hd-Oct, Humphrey Hfa, Clarus |
| Aerie Pharmaceuticals, INC. | $10,546.04 | 2019-2021 | |
| Alcon Vision LLC | $6,873.68 | 2021-2025 | Rocklatan, Voyager Dslt, Eysuvis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $5,236.66 | 2019-2021 | |
| Abbvie INC. | $1,355.47 | 2022-2025 | Durysta, Lumigan, Xen Glaucoma Treatment System |
| Johnson & Johnson Surgical Vision, INC. | $1,158.97 | 2019-2022 | |
| Allergan, INC. | $732.39 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $425.32 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $395.77 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $356.68 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $331.33 | 2022-2025 | Miebo, Alrex, Lotemax Sm |
| Biotissue Holdings INC. | $230.28 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $145.97 | 2019-2020 | |
| Thea Pharma INC. | $138.05 | 2022-2025 | Iyuzeh |
| Sight Sciences, INC. | $137.21 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $93.75 | 2024-2025 | Iheezo, Vevye |
| Mallinckrodt Hospital Products INC. | $74.02 | 2025 | Acthar |
| Kala Pharmaceuticals, INC. | $66.71 | 2019-2022 | |
| Iridex Corporation | $64.83 | 2019-2021 | |
| Glaukos Corporation | $38.63 | 2025 | Epioxa |
| Rxsight INC | $38.31 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Dompe US, INC. | $29.54 | 2025 | Oxervate |
| Amgen INC. | $28.11 | 2025 | Tepezza |
| Beaver-Visitec International, INC. | $24.85 | 2021 | |
| Mallinckrodt Enterprises LLC | $21.91 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $17.07 | 2024 | Xdemvy |
| New World Medical,INC. | $13.85 | 2022 | |
| Rayner Intraocular Lenses Limited | $13.61 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Severin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.